Introduction
Mesenchymal stromal cells (MSCs) are adult, fibroblast-like multipotent cells characterized by the ability to differentiate into tissues of mesodermal origin, such as adipocytes, chondroblasts, and osteoblasts (Friedenstein et al., 1974; Pittenger et al., 1999) . First identified and isolated from the bone marrow (BM), MSCs can now be expanded from a variety of other tissues including adipose tissue (AT), umbilical cord blood (UCB), skin, tendon, muscle, and dental pulp (Im et al., 2005; Campagnoli et al., 2001; Kawashima, 2012) . MSCs can be isolated based on their ability to adhere to plastic culture dishes, and they are capable of significant expansion by consecutive in vitro passaging (Pittenger et al., 1999) .
Historically, a challenge that has faced the field has been the lack of uniform criteria to define MSCs, which has hindered efforts to compare results obtained from different experimental and clinical studies. In response to this challenge, the International Society for Cellular Therapy formulated minimal criteria for defining MSCs in order to create a broader consensus for more uniform characterization of these cells (Dominici et al., 2006) . Although there remains much debate over how to define such a broad population of cells, it is clear that some populations of MSCs are capable of exhibiting stem cell function in vivo (Keating, 2012; Sacchetti et al., 2007) .
In addition to their stem/progenitor properties, MSCs have also been shown to possess broad immunoregulatory abilities and are capable of influencing both adaptive and innate immune responses. Recent findings have demonstrated that MSCs actively interact with components of the innate immune system and that, through these interactions, they display both anti-inflammatory and proinflammatory effects (Keating, 2012; Le Blanc and Mougiakakos, 2012; Prockop and Oh, 2012) . This ability of MSCs to adopt a different phenotype in response to sensing an inflammatory environment is not captured in assays that are commonly used to characterize these cells, but it is crucial for understanding their therapeutic potential in immune-mediated disorders. Much of the characterization of these properties has been conducted in vitro, and there are outstanding questions about the degree to which they represent activities that are functionally relevant for endogenous and/or transplanted cells in vivo. The putative role of stromal cells in maintaining tissue homeostasis serves as the basis for their application in disorders resulting from autogeneic or allogeneic immune responses, including Graft-versusHost Disease (GvHD) and autoimmune disorders (Le Blanc et al., 2008; Duijvestein et al., 2010) and can be referred to as ''stromal cell therapy.'' The application of MSCs in these inflammatory disease settings suggests that the stem cell properties of MSCs, including their ability to engraft, may be independent from their ability to regulate tissue homeostasis.
Animal models are of critical importance for translating in vitro immune regulatory properties of MSCs into therapeutic application and dissecting mechanisms of efficacy. Although murine and human MSCs share properties such as multilineage differentiation capacity, they are also distinct with respect to other properties. A notable example of this divergence is the susceptibility of murine BM-derived MSCs to transform upon culture expansion. In addition, murine and human MSCs employ different effector molecules (i.e., nitric oxide [NO] and indolamine 2,3 dioxygenase [IDO] , respectively) for immune regulation, for example during suppression of T cell proliferation (Ren et al., 2008; Franç ois et al., 2012) . In some studies, human MSCs have been applied in mouse models of either immune competent or immune deficient mice. These differences should be taken into consideration when interpreting in vivo effects of murine MSCs, especially in light of efforts to look at clinical application of MSCs.
In this Review we discuss the regulatory properties of MSCs with respect to their ability to modify tissue homeostasis and inflammation. MSCs are sensors of inflammation and are able to adopt a proinflammatory or anti-inflammatory phenotype by interfering with innate and adaptive immune responses both in vitro and in vivo. For the sake of clarity, these integrated responses are discussed separately. In addition, a comparison between murine and human MSCs will be also be covered. Finally, the clinical application of MSCs in the setting of acute GvHD treatment and biomarker development will be reviewed.
MSCs as Sensors of the Inflammatory
Microenvironment: Impact of Innate Immunity Inflammation serves as a localized or systemic protective response elicited by infection, injury, or tissue destruction and serves to eliminate pathogens and preserve host integrity. Within hours after the onset of an inflammatory response, molecules expressed by pathogens or associated with tissue injury are recognized by Toll-like receptors (TLRs) present on innate effector cells. TLR ligation triggers phagocytosis and the release of inflammatory mediators, which may initiate innate immune responses that provide a first line of nonspecific defense, mainly through the activation of phagocytic cells, including macrophages and neutrophils (Gordon and Mantovani, 2011) . TLR ligation may not only activate phagocytic cells but also stromal cells, including MSCs, thus creating an inflammatory environment (Mantovani et al., 2013; Waterman et al., 2010 (Nemeth et al., 2010; Tomchuck et al., 2008; Delarosa et al., 2012) . Under hypoxic culture conditions, stimulation of MSCs with the proinflammatory cytokines IFN-g, TNF, IFN-a, and IL-1b upregulates expression of a subset of TLRs, thus increasing the sensitivity of MSCs to the inflammatory milieu . However, prolonged stimulation with TLR ligands causes downregulation of TLR2 and TLR4 (Mo et al., 2008) , most likely as a self-regulatory mechanism to prevent overactive skewing of the immune response.
To direct appropriate immune responses to a diversity of pathogenic insults, the different TLRs are activated by specific endogenous or pathogen-associated molecules, including lipopolysaccharide (LPS) from Gram-negative bacteria (TLR4) and double strand RNA (dsRNA) carried by some viruses (TLR3). Waterman et al. (2010) have suggested that MSCs may polarize into two distinctly acting phenotypes following specific TLR stimulation, resulting in different immune modulatory effects and distinct secretomes. The TLR4-primed MSC population exhibits a proinflammatory profile (MSC1) and the TLR3-primed MSC population delivers anti-inflammatory signals (MSC2) (Figure 1 ). Although the molecular pathways that promote a proinflammatory or anti-inflammatory secretome following TLR ligation remain unclear, the concept of MSC polarization into proinflammatory and anti-inflammatory cells provides an attractive model to explain and interrogate the apparently contradictory roles of MSCs in inflammation.
Within the innate immune system, it is well established that macrophages are key players in initiating and controlling inflammation (Mantovani et al., 2013) , and MSCs can influence macrophage function depending on the inflammatory context (see sections below). Monocytes arriving at an inflammatory environment can develop into activated M1 macrophages or convert into alternatively activated M2 macrophages depending on microenvironmental cues. While M1 macrophages stimulate (Ren et al., 2008; Li et al., 2012) . These chemokines bind to receptors present on T cells, i.e., CCR5 and CXCR3. Polarization to a proinflammatory MSC1 phenotype can also be influenced by activation of TLR4 by low levels of lipopolysaccharide (LPS) derived from Gram-negative bacteria. The levels of immune-suppressive mediators, such as IDO and NO, are low when the MSC1 phenotype is adopted. The balance between these opposing pathways may serve to promote host defense on one hand and at the same time create a loop that prevents excessive tissue damage and promotes repair. local inflammation by releasing proinflammatory cytokines, M2 macrophages secrete a combination of cytokines (including high levels of IL-10 and TGF-b1 and low levels of IL-1, IL-6, TNF-a, and IFN-g) that together exert an anti-inflammatory effect and allow tissue regeneration following inflammation (Mantovani et al., 2013) .
MSCs actively interact with components of the innate immune system and influence their subsequent immunoregulatory and regenerative behavior (Keating, 2012; Le Blanc and Mougiakakos, 2012) . The production of proinflammatory cytokines by M1 macrophages or activated T cells may activate MSCs and trigger the release of mediators that skew the differentiation of monocytes toward an anti-inflammatory profile and ultimately toward M2 macrophages (Le Blanc and Mougiakakos, 2012) ( Figure 2 ). In addition to polarization of MSCs, macrophage polarization provides a supplementary mechanism to maintain balance between proinflammatory and anti-inflammatory effects. This dynamic regulatory feedback between MSCs and macrophages generates a profound sensitivity to the surrounding microenvironment that is displayed through the ability to switch between proinflammatory and anti-inflammatory activities. In both cases, switching mechanisms rely on the production of soluble mediators, including the immunosuppressive factors inducible NO synthase (iNOS, for mice) and IDO (for humans), which are induced by proinflammatory cytokines. The concentrations of these factors may be critical in triggering the switch between proinflammatory and anti-inflammatory MSCs and, thereby, also between M1 and M2 macrophages (Ren et al., 2008) .
MSCs Enhance Immune Responses during Early-Stage Inflammation
The proinflammatory activities of MSCs may be beneficial in the early phase of inflammation and help in mounting a proper immune response. During the acute phase of inflammation, neutrophils migrate toward the site of inflammation where they accumulate within minutes and act mainly through phagocytosis (Kolaczkowska and Kubes, 2013) . In mice, the recognition of microbial molecules by tissue-resident MSCs results in increased production of growth factors, such as IL-6, IL-8, granulocytemacrophage colony-stimulating factor (GM-CSF), and macrophage migration inhibitory factor (MIF), that recruit neutrophils and enhance their proinflammatory activity (Brandau et al., 2010) . Moreover, TLR3-activated human BM-MSCs (MSC2) promote the in vitro survival of resting and activated neutrophils in an IL-6-, IFN-b-, and GM-CSF-dependent manner (Cassatella et al., 2011) .
In addition to neutrophils, immune responses may be enhanced by MSCs through the production of chemokines that recruit lymphocytes to sites of inflammation. Human MSCs produce the chemokines CXCL-9, CXCL-10, and CXCL-11 upon stimulation with proinflammatory cytokines. In vitro studies with murine and human MSCs suggest that these stimulatory effects only occur when MSCs are exposed to insufficient levels of proinflammatory cytokines, such as TNF-a and IFN-g. Under these immune-enhancing conditions, murine MSCs elicit insufficient levels of NO to inhibit T cell proliferation. Indeed, inhibition of iNOS or its genetic ablation resulted in strong enhancement of T cell proliferation by murine MSCs (Ren et al., 2008; Li et al., 2012; Shi et al., 2012) . Under similar conditions, human MSCs produce insufficient IDO (rather than iNOS) to suppress T cell proliferation ( Figure 1 ). These data suggest that iNOS for murine cells or IDO for human cells may serve as a molecular switch between immune-suppressive to immune-enhancing effects of MSCs. phenotype to dampen inflammation and promote tissue homeostasis through polarization toward anti-inflammatory cells and M2 macrophages in vitro. Coculture of monocytes with human or mouse BM-MSCs promotes the formation of M2 macrophages (Eggenhofer and Hoogduijn, 2012) (Figure 2 ) and this is dependent on both cellular contact and soluble factors, including prostaglandin E2 (PGE2) and catabolites of IDO activity such as kynurenine (Né meth et al., 2009; Eggenhofer and Hoogduijn, 2012) . Moreover, activation of MSCs with IFN-g, TNF-a, and LPS increases the expression of cyclooxygenase 2 (COX2) and IDO in BM-MSCs, thereby further promoting a homeostatic response toward M2 macrophage polarization (Né meth et al., 2009; Franç ois et al., 2012) . Through the release of chemokine (C-C motif) ligands CCL2, CCL3, and CCL12, human and mouse BM-MSCs can recruit monocytes and macrophages into inflamed tissues and promote wound repair (Chen et al., 2008) .
MSCs Suppress Immune Responses and Inflammation to Promote Tissue Homeostasis
This polarizing effect of MSCs on M2 macrophages is closely linked with the ability of MSCs to favor the emergence of regulatory T cells (Tregs), which are involved in immunosuppression. TGF-b is a factor that is constitutively produced by MSCs and that directly induces Tregs in a monocyte-dependent manner. M2 polarized macrophages also produce IL-10, which is directly immune suppressive. In addition, M2 macrophages produce CCL18, a factor that in conjunction with TGF-b promotes the generation of Tregs (Melief et al., 2013a) ( Figure 2 ). The MSC-derived factors that induce the differentiation of monocytes toward M2 macrophages have not been identified.
These data underline the importance of the interactions between MSCs and the innate immune system in balancing proinflammatory and anti-inflammatory responses in order to preserve tissue integrity. The central role of macrophages in the induction of the anti-inflammatory effect of MSCs is depicted in Figure 2 .
Role of MSCs in Orchestrating Adaptive Immune Responses
The adaptive immune system is antigen-specific and allows the development of immunological memory. It comprises CD4 + T-helper and CD8 + cytotoxic T lymphocytes that deliver a tailored antigen-specific immune response following antigen processing and presentation by antigen-presenting cells (APCs). T helper cells comprise a subpopulation of cells, Tregs, which are specialized in suppression of T cell-mediated immune responses. The innate immune system plays a crucial part in the initiation and subsequent direction of adaptive immune responses, as well as in the removal of pathogens that have been targeted by an adaptive immune response (Yamane and Paul, 2013; Gratz et al., 2013) . MSC and Effector T Cell Immunity As with innate immunity, much of what is known about the interaction of MSCs with the adaptive immune system is through in vitro studies. MSCs are able to suppress in vitro T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli (Di Nicola et al., 2002) through the secretion of soluble factors that include TGF-b, Hepatocyte Growth Factor (HGF), PGE2, IDO, NO, and hemoxygenase (HO) (Stagg and Galipeau 2013) . The release of these suppressive factors is enhanced following stimulation of MSCs with TNF-a and IFN-g, although unstimulated MSCs also produce these mediators. In human cells IDO promotes the degradation of tryptophan into kynurenine and other catabolites that have been shown to not only suppress T cell proliferation, but also induce Treg differentiation. The suppression of T cell proliferation involves both CD4 + and CD8 + T cells; IFN-g production and cytotoxicity are also inhibited in a dose-dependent manner (Krampera et al., 2003; Aggarwal and Pittenger, 2005) . In murine cells, the critical role of NO in suppressing T cell proliferation is also supported by the observation that in vitro proliferation of murine T cells is boosted by the addition of the NO inhibitor L-NMMA . Similarly, addition of iNOS À/À MSCs induces a dramatic increase in T cell proliferation in coculture assays. While MSCs directly produce soluble factors that suppress T cell proliferation, it has also been suggested that the ability of MSCs to suppress T cell proliferation in vitro is monocyte dependent, since MSCs show a reduced inhibitory action on T cells in the absence of monocytes (Cutler et al., 2010; Franç ois et al., 2012) .
MSCs and Regulatory T Cells
Several studies have documented the ability of MSCs to polarize T cells toward a regulatory phenotype (Burr et al., 2013 ) that serves as an important mechanism by which MSCs dampen inflammation. Tregs comprise a subpopulation of T helper cells, are specialized in suppression of T cell-mediated immune responses, and characteristically express the forkhead box P3 (FoxP3) transcription factor. There are two main subsets of Tregs including a population of FoxP3 + natural Tregs, which are thymus derived and specific for self antigens and induced or adaptive Tregs that are derived from mature CD4 + CD25
À

Foxp3
À precursors in the periphery following inflammatory stimuli (Chaudhry and Rudensky, 2013 + -expressing regulatory T cells (induced Tregs), a process involving direct MSC contact with helper T cells and PGE2 and TGF-b secretion (Maccario et al., 2005; English et al., 2009) . The generation of Tregs was reported to be monocyte dependent and was not observed in cocultures of MSCs and purified CD4 + T cells or monocyte-depleted
PBMCs, but it could be restored by the addition of monocytes (Melief et al., 2013a) . Following addition of mitogen-stimulated T cells, MSCinduced Tregs potently suppressed the T cell proliferative response (English et al., 2009) . Secretion of HLA-G5 by MSCs has also been shown to promote MSC-induced Treg generation. Blocking experiments using neutralizing anti-HLA-G antibody demonstrated that HLA-G5 contributes first to the suppression of allogeneic T cell proliferation and then to the expansion of CD4 + CD25 + FoxP3 + Tregs (Selmani et al., 2008) .
In this process, both the activation state of CD4+ T cells and the cytokine milieu may play a role. By exerting inhibitory effects on APCs that process antigens and present them to T cells, MSCs can generate regulatory APCs characterized by their Treg-promoting activity. All together, these studies indicate that MSCs are able to recalibrate the balance between inflammatory effector T cells and anti-inflammatory Tregs. This process is tightly related to polarization of monocytes toward anti-inflammatory (M2) macrophages (Figure 2) . By linking cytokine-mediated immune suppression (i.e., IL-10 production) and the induction of Treg cells, an amplification of the anti-inflammatory response is obtained.
In Vivo Regulation of Inflammation by MSCs
Ex-Vivo-Expanded MSCs Influence Macrophage Polarization and Immune Responses In Vivo While the concept of macrophage polarization may explain the apparent discrepancy between proinflammatory and anti-inflammatory activities of MSCs, the biological relevance of these findings remains unclear. In several recent studies, the ability of MSCs to polarize macrophages has also been investigated in vivo. In a sepsis model, the administration of mouse BMMSCs decreased lethality; however, this effect was not observed after macrophage depletion or after administration of IL-10-specific neutralizing antibodies, suggesting that MSC-induced macrophage polarization also occurs in vivo and may result in reduced tissue damage (Né meth et al., 2009) . It has been recently observed that Nes + MSCs respond to TLR4 ligation by upregulating monocyte chemotactic protein-1 (MCP1) expression, which induces CCR2-dependent migration of monocytes from the BM into the circulation, which may serve as a mechanism to further promote this process (Shi et al., 2011) . In the same model, MSCs improved survival of mice by enhancing the ability of neutrophils to phagocytize bacteria and promote bacterial clearance (Hall et al., 2013; Né meth et al., 2009) . It was also shown that MSCs, through the induction of IL-10 by monocytes and macrophages, can prevent neutrophils from migrating into tissues, thereby preventing oxidative damage. The inhibition of neutrophil migration into tissues is associated with a higher neutrophil count in the blood, allowing more efficient bacterial clearance and, at the same time, preventing excessive tissue damage. These data suggest that during the early phase of inflammation, MSCs may play a role in promoting neutrophil migration and activation in order to enhance innate immune responses, but during later stages, they may switch toward an inhibitory phenotype resulting in inhibition of migration to protect tissues against oxidative injury.
Similar observations were made in a model of endotoxininduced lung injury, in which intrapulmonary delivery of mouse BM-MSCs decreased the production of TNF-a and chemokine ligand CXCL2 and increased the production of IL-10 by alveolar macrophages (Gupta et al., 2007) . On the same line, in a zymosan-induced peritonitis model, infusion of human BMMSCs resulted in secretion of TNF-stimulated gene 6 (TSG6), a molecule that interferes with TLR2 nuclear factor-kB (NF-kB) signaling in peritoneal macrophages, thereby attenuating their activation (Choi et al., 2011) . In this model the therapeutic effects of MSCs seem to be mediated by endocrine rather than paracrine mechanisms, suggesting that homing to a site of injury is not necessarily required for therapeutic efficacy.
The role of macrophages in MSC-induced Treg formation has been recently confirmed in mouse models of fibrillin-mutated systemic sclerosis and experimental colitis. Infusion of murine BM-MSCs induced transient T cell apoptosis, which triggered macrophages to produce high levels of TGF-b, eventually enhancing CD4 + CD25 + FoxP3 + Treg generation. This effect translated into amelioration of the disease phenotype (Akiyama et al., 2012) . The polarization of T cells toward a Treg phenotype has been also shown in other experimental models of autoimmune and inflammatory diseases, such as SLE, diabetes, and colitis (Choi et al., 2012; Madec et al., 2009; Duijvestein et al., 2011) .
Injection of iNOS À/À MSCs into the footpad of mice generated an aggravated response to ovalbumin-induced Delayed Type Hypersensitivity (DTH) as measured by an increase in footpad thickness and enhanced leukocyte infiltration. Conversely, administration of unmodified MSCs reduced footpad thickness and leukocyte infiltration. These results confirm the dual regulatory role of NO in enhancing or suppressing T cell immunity (Ren et al., 2008; Li et al., 2012) . Insufficient homing of systemically delivered MSCs is considered a major limitation of MSC-based therapies, caused in part by inadequate expression of cell surface adhesion receptors. The modification of human MSC surface with a construct containing sialyl Lewis(x) that is found on the surface of leukocytes and mediates cell rolling within inflamed tissue has been shown to allow rolling of MSCs on inflamed endothelium in vivo in mice and homing to inflamed tissue with higher efficiency compared with native MSCs (Sarkar et al., 2010) . This model has been taken one step further by the overexpression of IL-10 in engineered MSCs. The systemic administration of these cells in an ear-inflammation model resulted in a superior anti-inflammatory effect in vivo that was dependent on rapid migration to the inflamed ear. In spite of the rapid clearance of MSCs from the circulation following systemic injection (Lee et al., 2009) , these results show that MSCs can be successfully used for the targeted delivery of immune-suppressive molecules to distant sites of inflammation (Levy et al., 2013) .
Taken together, these in vivo results indicate that MSCs actively interact with cells of the innate immune system and modulate their function to establish a fine balance between pathogen elimination and repair processes, aiming at controlling inflammation, preventing organ failure, and preserving tissue homeostasis. The further elucidation of mechanisms that trigger a functional switch between MSC phenotypes remains an important research goal for future studies.
MSCs Are Responsive to the Host Microenvironment and Participate in Immune Surveillance
Several reports have indicated that MSCs are not constitutively inhibitory but need to be activated by an inflammatory environment in the host in order to have their immunoregulatory effect mediated (Krampera, 2011) . This notion was based on the observation that anti-IFN-g receptor antibodies can block the suppressive effect of MSCs. The simultaneous presence of other inflammatory cytokines can influence the immunosuppressive effect of MSCs as well as induce changes in their immunophenotype. IFN-g, TNF-a, and IL-1b are able to induce the upregulation of HLA-class I, ICAM-1, and VCAM-1 on the surface of MSCs, while IFN-g alone can induce the activity of IDO (Ren et al., 2008) . Inflammatory stimuli induce MSCs to secrete molecules involved in the regulation of tissue homeostasis, including NO, IDO, PGE2, HO-1, TSG6, CCL2 chemokine, IL-10, and galectins .
According to the activation model, MSCs are most effective when administered after the onset of an inflammatory response. In a mouse GvHD model, MSC administration on the same day of bone marrow transplantation (BMT) had no protective effect (Sudres et al., 2006) , whereas administration 3, 8, or 20 days after BMT significantly suppressed the progression of GvHD and abrogated the related symptoms (Polchert et al., 2008) . It has been proposed that pretreatment of MSCs with inflammatory cytokines may mimic the inflammatory environment and may enhance their potential therapeutic efficacy. In support of this theory, administration of IFN-g-pretreated MSCs protected mice from GvHD-induced death (Polchert et al., 2008) . Other studies have indicated that pretreatment with inflammatory cytokines can amplify the therapeutic effect of MSCs in animal models of colitis and acute myocardial ischemia/reperfusion injury (Duijvestein et al., 2011; Luo et al., 2012) . These data indicate the importance of the local inflammatory conditions in regulating the anti-inflammatory effects of MSCs. Further dissection of the molecular mechanisms involved in these interactions will be crucial for the development of novel MSC-based therapies.
There is ample evidence that administration of ex vivo expanded MSCs may exert immune-suppressive properties in vivo, for instance by inducing macrophage polarization. However, it is still unclear to what extent primary MSCs in the host play a similar regulatory role. As part of the BM niche, MSCs support hematopoiesis and restore the differentiated compartment of osteoblasts and adipocytes during tissue growth and turnover (Sacchetti et al., 2007) . Park et al. (2012) showed that a subset of Nestin + MSCs present in vivo are able to replace short-lived mature osteoblasts to maintain homeostasis and respond to bone injury. MSCs may also be involved in tumor progression in a wide range of cancers. Through the release of soluble factors, tumor cells may recruit myeloid cells from the BM to the tumor microenvironment, where they subsequently promote tumor progression by conversion into potent immune suppressive cells, including M2-like Tumor Associated Macrophages (TAMs). TAMs promote tumor growth by producing proangiogenic vascular endothelial growth factor (VGEF) and immune-suppressive factors (PGE2, TGF-b) and by releasing chemo-attracting factors (CCL22) that recruit Tregs (Gabrilovich et al., 2013) . Recent evidence indicates that BM-derived MSCs can also be targeted to the tumor microenvironment by factors such as stromal cell-derived factor 1 (SDF-1), platelet-derived growth factor a (PDGF-a), and VEGF (Gabrilovich et al., 2013; Ke et al., 2013; Ren et al., 2012) . In the tumor microenvironment MSCs may be conditioned into tumorresident MSCs that acquire functions that are distinct from those of normal tissue MSCs. One of the mechanisms through which tumor-resident MSCs promote tumor growth involves the production of CCL2, the major chemokine for monocyte trafficking, which results in the recruitment of immune-suppressive macrophages. The chemokine profile and the tumor-promoting properties of tumor-resident MSCs can be mimicked by stimulating normal BM-derived MSCs with TNF-a, suggesting that inflammation drives tumorigenesis by establishing a link between MSCs and monocytes and macrophages Guilloton et al., 2012) . While their tumor-promoting properties have been firmly established, other reports suggest that preactivation of human MSCs with TNF-a may result in tumor-suppressing activity mediated by upregulation of TRAIL on MSCs and by induction of TRAIL-dependent apoptosis of tumor cells (Lee et al., 2012) . The apparent discrepancy between these reports may be explained by the use of adoptively transferred cells by Lee et al. that do not necessarily represent the physiological reality (Mantovani, 2012 ). In addition, Lee et al. have used a xeno transplant model (NOD-SCID), in which adaptive immune (suppressive) and tumor-promoting responses are lacking. Although mechanisms through which MSCs may promote or suppress tumor progression are not fully clarified, the possible tumor-promoting activity of MSCs should be carefully considered in choosing MSCs for application in cancer patients.
It has been suggested that MSCs play a role in maintaining fetal maternal tolerance in the placenta and that they express molecules known to be involved in this process. Both UCBand BM-derived MSCs express HLA-G, either in its soluble form or as a surface antigen (Selmani et al., 2008) . It is conceivable that HLA-G expression at the feto-maternal interface is one of the factors protecting the fetus from maternal immune attack (Carosella et al., 2008) . The expression of HLA-G by MSCs could contribute to their ability to blunt excessive immune responses in a specific environment and to control inflammation and maintain homeostasis. IDO represents another molecule involved in the maintenance of fetal maternal tolerance and may also be produced by MSCs.
Different Biological and Functional Properties of MSCs: Mouse and Man
While animal models may play a crucial role in dissecting efficacy, it is important to note that murine MSCs are intrinsically different from human cells (Table 1) . Ex vivo expansion with murine cells is slower than with human cells, and murine MSCs require weeks before entering a linear growth rate (Phinney et al., 1999) . At this stage, murine MSCs undergo transformation and immortalization in culture. Several reports have indicated that transformed murine MSCs have an increased proliferation rate, display an altered morphology, carry cytogenetic abnormalities, and form tumors following injection into syngeneic mice. Murine BM-derived MSCs in long-term culture gradually exhibit increased telomerase activity and proceed to a malignant state, resulting in sarcoma formation in vivo (Miura et al., 2006; Tolar et al., 2007) . This susceptibility to malignant transformation may be attributed to the high degree of chromosomal instability in genetically unstable inbred mice, characterized by the development of both structural and numerical aberrations even at early culture passages. Therefore, culture-expanded murine MSCs should be regarded as transformed cells, even in the absence of a malignant phenotype. In contrast with these findings, (malignant) transformation of human MSCs has not been directly demonstrated and attempts to induce a malignant phenotype by long-term ex vivo expansion have been unsuccessful (Bernardo et al., 2007) . In a recent report, its likelihood has been estimated to be <10 À9 (Prockop et al., 2010) (Table 1 ).
Many effector molecules that are thought to be involved in the induction of MSC-mediated immunosuppression are divergent between mice and humans, although some similarities can be found. Release of IFN-g by target cells induces the release of IDO by human MSCs, which is responsible for the inhibition of T cell proliferation (Krampera, 2011) . In mice, IFN-g and TNF-a stimulates chemokine production by MSCs, resulting in T cell attraction and increased iNOS, which subsequently produces NO for inhibition of T cell proliferation (Ren et al., 2008) . Not all immunoinhibitory molecules are divergent between mice and humans, and PGE2 represents a molecule with a conserved role in MSC-mediated immunoregulation in both humans and mice. While human PGE2 and other factors produced by human MSCs have been shown to participate in the inhibition of T cell proliferative responses in vitro , PGE2, in conjunction with NO, has been reported to induce an inhibitory IL-10-secreting macrophage phenotype in LPS-containing cocultures in mice (Né meth et al., 2009) . Moreover, PGE2 and IL-6 produced by human MSCs are, at least in part, responsible for the shift of M0 macrophages into IL-10-producing cells in vitro (Melief et al., 2013b; Ghannam et al., 2010) .
The dissimilarities between MSCs isolated from murine and human species require a careful evaluation when choosing animal models to test MSCs in preclinical studies. The contribution of murine models employing murine/human cells to the development of MSC therapy in humans may be limited by the species differences, as shown for the prevention and treatment of GvHD. In this context, several animal studies have addressed the suppressive effect of MSCs, with conflicting results. In one study, human AT-derived MSCs have been infused systemically in mice early after transplantation of haploidentical hematopoietic stem cells (HSCs) and were able to rescue the animals from lethal GvHD (Yañ ez et al., 2006) . Sudres et al. (2006) have reported that a single dose of murine C57BL/6 BM-derived MSCs at time of allogeneic BM transplantation did not affect the incidence and severity of GvHD in BALB/c mice, whereas human UCB-derived MSCs administered at weekly intervals were able to prevent GvHD development after allogeneic transplantation of human PBMCs in NOD/SCID mice (Tisato et al., 2007) . The same cells were not effective when administered prophylactically immediately after PBMC infusion, nor when they were infused late in the course of GvHD development. Polchert et al. (2008) tested the ability of MSCs to prevent GvHD by administering a single dose of BALB/c BM MSCs into C57BL/6 mice at different time points. A significant increase in survival of the recipient mice was only observed if MSCs were injected at day +2 or +20 after the allograft. At these time points the levels of IFN-g were found to be high in the animals, supporting the notion that MSCs need to be activated by inflammatory cytokines to deliver their immunosuppressive effect.
The mixed results of MSC treatment on GvHD prevention and the little effect of MSC infusion on established GvHD reported in these studies remain unexplained. These discrepancies may be related to differences between humans and mice in the pathogenesis of GvHD. In addition, they may be caused by differences in the biological and functional properties of MSCs or by subtle differences in the inflammatory status of the host, resulting in a proinflammatory or anti-inflammatory MSC secretome. Finally, they could also be affected by differences in the experimental models employed. Most data have been derived from Growth pattern linear growth lag phase followed by linear growth (Phinney et al., 1999) Presence of chromosomal abnormalities rare a (Tarte et al., 2010; Ben-David et al., 2011) invariable (Miura et al., 2006; Tolar et al., 2007) Transformation and immortalization not reported (Bernardo et al., 2007; Prockop et al., 2010) frequent (Miura et al., 2006; Tolar et al., 2007) Expression MHC-mismatched models that do not fully reflect human allotransplantation. Indeed, reports in murine models contrast with observations in clinical trials, where MSC treatment has been effective in suppressing established GvHD (Le Blanc et al., 2008) but has little effect on GvHD (Lazarus et al., 2005) . These differences may relate to the use of different immune effector molecules between mice and human MSCs (i.e., IDO versus NO) but may also result from lack of cross-species reactivity of cytokines. IFN-g is species specific and, therefore, human MSCs cannot be activated in vivo by mouse IFN-g, but can still be stimulated by TNF-a since it is not species specific. In spite of the crucial differences in the use of effector molecules and the lack of cross-species reactivity of key cytokines such as IFN-g, human MSCs have shown therapeutic effects in mouse models of GvHD (Tisato et al., 2007) . However, with the exception of TSG-6 (Lee et al., 2009) , the mechanisms of efficacy in these models remain as yet unclear.
Although MSCs have been applied in a variety of disease models, including experimental autoimmune encephalomyelitis (EAE), colitis, retinitis, and myocardial infarction, results are sometimes difficult to reproduce. Strain-specific induced disease models may suffer from experimental fine-tuning in order to arrive at an anticipated outcome. Therefore, there remains a need for robust animal models to test the in vivo modulatory properties of MSCs, and data derived from one model in a single strain may not be sufficient.
Anti-Inflammatory Effects of MSCs in the Clinic: Treatment of GvHD as a Case Study
Stromal therapy in patients with steroid-refractory acute GvHD (aGvHD) occurring after allogeneic HSCT and/or donor lymphocyte infusion is one of the most extensively investigated potential clinical applications of MSCs. Following the first report on a pediatric patient experiencing grade IV treatment refractory aGvHD who was rescued by the infusion of BM-derived MSCs (Le Blanc et al., 2004 ), a multitude of pilot studies have been performed. A phase II, multicenter clinical trial showed a clinical response in the majority of patients (55 adults and children) with steroidresistant aGvHD treated with intravenous infusion(s) of allogeneic MSCs. This response translated into a significant difference in survival between complete responders and partial/nonresponding patients (Le Blanc et al., 2008) . These results have been extended in a cohort of 37 pediatric patients treated with multiple infusions of MSCs (Ball et al., 2013) . Similar results have been reported in a smaller cohort of pediatric patients treated with platelet-lysate (PL)-expanded MSCs (Lucchini et al., 2010) . Clearly, these findings need to be confirmed in prospective randomized studies.
The identification of biomarkers that enable evaluation and quantification of MSC efficacy is of paramount importance for the development of MSC therapy. Unfortunately, clinical studies regarding efficacy of MSC treatment have only rarely been used to identify biomarkers predicting response to MSCs. One approach could be that of analyzing clinical samples from GvHD patients treated with MSC infusion(s) to understand the events underlying patient response in vivo. Dander et al. (2012) analyzed plasma levels of two biomarkers for aGvHD, i.e., interleukin 2 receptor alpha (IL-2Ra) and tumor necrosis factor receptor (TNFR) I, in a group of patients with aGvHD before and after MSC treatment. While the levels of the two factors were elevated before MSC infusion, they persistently decreased in responder patients, suggesting that these phenomena were related. Interestingly, the same authors observed that one of the patients responding to MSC treatment showed a decrease in the biomarker concentrations. Thereafter the patient developed chronic GVHD (cGvHD) that did not respond to an additional infusion of MSCs, and the patient's IL-2Ra and TNFRI levels remained stable or even increased after the infusion. This observation is in line with several studies indicating that MSCs need to be activated by an inflammatory environment to deliver their therapeutic effect (Krampera, 2011) . This environment may be more frequently present during established aGvHD than in cGvHD.
The available evidence suggests that responses to MSC treatment may be independent of the MSC donor or dose of the immune-suppressive treatment employed. This heterogeneity in response might be related to the presence or absence of the appropriate environment in the patient capable of activating MSCs. Strategies to understand the ongoing patient inflammatory status at the time of MSC infusion could, therefore, allow the development of relevant biomarkers. It is conceivable that heterogeneity in responses could be mainly related to host factors, including an appropriate proinflammatory microenvironment, rather than a result of product-related factors. The consequence of this possibility is that product-related potency assays may be of relatively little value.
Conclusions and Future Directions
We have reviewed here the regulatory properties of MSCs in immune-mediated or inflammatory conditions, emphasizing the central role of the innate immune system in the modulatory effects of MSCs. In particular, we have highlighted the prominent role of monocytes/macrophages in orchestrating both proinflammatory and anti-inflammatory responses (see Figure 2 ).
While this model is supported by in vitro and animal studies (Dazzi et al., 2012; Le Blanc and Mougiakakos, 2012) , it should be noted that it remains to be demonstrated to what extent these pathways are operational in vivo. There are many outstanding questions about the physiological role of MSCbased immune modulation that will need to be addressed to support further development of their clinical application. While prospective randomized clinical trials aiming at demonstrating efficacy and safety are warranted, an adequate understanding of the underlying mechanisms is required to realize their therapeutic potential. An important consequence of the polarization concept is that immunomodulatory effects of MSCs will be largely determined by local inflammatory conditions in the host. Timing and route of delivery of MSC treatment may, therefore, be critical in determining the treatment responses in patients. Biomarkers predictive for response are not yet available, but the notion that early treatment with MSCs for steroid-resistant aGvHD may be more effective than treatment initiated later in the course of GvHD is in accordance with this hypothesis (Ball et al., 2013) .
There is a clear need to develop animal models that appropriately address the complex interplay between the ''MSC product'' and the host microenvironment where these cells execute their regulatory function. Insight into the in vitro modulatory networks that result in the generation of anti-inflammatory Cell Stem Cell 13, October 3, 2013 ª2013 Elsevier Inc. 399
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Review cells (M2 macrophages, Tregs) may help to design relevant models to address these issues.
Regarding their therapeutic effect, MSCs may serve as drug delivery vehicles at local sites of inflammation. Novel molecular tools aimed at defining the MSC secretome, proteome, and transcriptome are being employed to more precisely define the soluble factors that mediate MSC function (Ranganath et al., 2012) . These tools include MSC-derived microvesicles or exosomes that can mediate intercellular communication between MSCs and other cells (Biancone et al., 2012) . As far as the endocrine effects of MSCs are concerned, it is conceivable that identification of relevant effector molecules could lead to novel treatment modalities that might eventually replace cellular therapy with MSCs. However, the effector functions of MSCs may also depend on paracrine mechanisms that are mediated by the concerted interaction between different molecules that are delivered locally through the directed migration of cells to a site of injury. This complexity must be considered when designing novel therapeutic strategies with MSCs. The latter strategy would open the possibility to direct migration and engineer MSCs in order to deliver effector molecules at particular (tissue-specific) sites (Sarkar et al., 2010; Levy et al., 2013) .
MSC therapy has entered the clinic in a variety of applications related to tissue repair and alloimmune or autoimmune disorders (Le Blanc et al., 2008; Duijvestein et al., 2010) . According to the clinical trial registry at the National Institute of Health, over 350 clinical trials are currently being conducted with these cells (http://clinicaltrials.gov). Other potentially promising indications include the use of MSCs in solid organ transplantation with the aim of reducing the use of immune-suppressive drugs or treating chronic rejection (Casiraghi et al., 2013) . The potential use of MSCs in tolerance induction in organ transplantation relates to their ability to skew the balance between effector T cells and regulatory T cells. In autoimmune disorders, the use of MSC therapy in luminal Crohn's disease or Crohn's fistulas is currently under study (Ciccocioppo et al., 2011) .
MSC therapy represents an emerging modality of alternative treatment with the capacity to provide site-specific immunoregulation to control pathogenic T cell responses that drive autoimmunity and allograft rejection. Prospective randomized studies are needed to determine the true scope of the therapeutic potential and provide clear evidence of reproducible efficacy. Nevertheless, this promising property of MSCs, independent of their HSC-supporting capacity, warrants extensive further study.
